XenoPort (XNPT) Stock Purchasers File Securities Fraud Class Action Lawsuit Complaint Against XenoPort, Inc. Over Alleged Representations About XenoPort’s Phase 3 Clinical Program for Horizant (Gabapentin Enacarbil) a/k/a XP13512 As A Potential Treatment for Restless Legs Syndrome (“RLS”).
A securities fraud class action lawsuit was filed against XenoPort, Inc. and certain XenoPort executive officers and directors (collectively the “Defendants”) in the United States District Court for the Northern District of California on behalf of a class consisting of all those who purchased or otherwise acquired the common stock of XenoPort, Inc. between May 5, 2009 and February 17, 2010 inclusive (the “Class”), alleging that XenoPort violated federal securities fraud laws by issuing false and misleading financial information to investors, according to class action lawsuit news reports.
The XenoPort securities fraud class action lawsuit complaint reportedly alleges that XenoPort made false and misleading statements about XenoPort’s Phase 3 clinical program for an extended-release tablet and development stage drug called Horizant (gabapentin enacarbil), also known as XP13512 (“512”), as a potential treatment for moderate-to-severe primary Restless Legs Syndrome (“RLS”). The XenoPort securities fraud class action lawsuit complaint reportedly alleges that defendants failed to disclose that 512 had earlier shown an increased occurrence of pancreatic cancer in lab rats.
If You Have Thoughts On The XenoPort Securities Fraud Class Action Lawsuit, Share Your Class Action Comments Below.